ACK1 Inhibitors
2 drugsAbout ACK1
ACK1, or Activated CDC42 Kinase 1, is a non-receptor tyrosine kinase involved in cell growth, survival, and migration. Dysregulation of these processes makes ACK1 a compelling oncology target.
While there is no genetic evidence directly linking ACK1 to specific diseases, its role in cancer-related cellular processes supports therapeutic intervention. Two FDA-approved drugs targeting ACK1 highlight its clinical relevance.
ACK1 is targeted by two FDA-approved small molecule drugs: ZELBORAF (Roche) and TAGRISSO (AstraZeneca). These drugs are approved for oncology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 85% attractiveness score.
- White space opportunity in Advanced Lung Non-Small Cell Carcinoma with only 4 trials.
- phase3 represents biological uncertainty with 33% completion.
Top Drugs
The competitive landscape consists of Roche and AstraZeneca, each with approved ACK1-targeting drugs.
The limited number of companies indicates a relatively unconcentrated market with potential entry points.
Drug Modality Landscape
Modalities
Routes of Administration
ACK1 is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities suggests an opportunity to explore antibody or PROTAC-based ACK1 therapeutics.
Clinical Trials 339 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 121 | 54 | 23 | 43 | 70% |
| Phase 2 | 167 | 44 | 22 | 101 | 67% |
| Phase 3 | 42 | 10 | 4 | 28 | 71% |
| Phase 4 | 9 | 4 | 2 | 3 | 67% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved ACK1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ACK1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2011 - 2015)
The first ACK1-targeting drug was approved in 2011 (ZELBORAF), with the most recent approval in 2015 (TAGRISSO).
The relatively short approval span suggests a potentially maturing target with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 6 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 259 clinical trials targeting ACK1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities